China making big gains in drug R&D jobs state covets

Back to TopCommentsE-mailPrintBookmark and Share
Greg Andrews

JIANGSU PROVINCE, China—If you needed further confirmation that Eli Lilly and Co.’s influence as an Indiana employer will continue to wane, look no further than the labs of Crown Bioscience outside Shanghai.

Here in a gleaming new building, Crown employees are conducting high-end early-stage research on new drugs—and doing so at what by U.S. standards are bargain-basement prices.

The total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown is one-third of that, said Chuan “Joe” Shih, Crown’s executive vice president of integrated drug discovery.

Shih Former Lilly researcher Shih helps lead one of the many drug R&D firms in the Shanghai area.

The Taiwanese-born Shih ought to know. He spent 25 years as a researcher at Eli Lilly, attaining the lofty company title of distinguished scholar. He left two years ago for the senior management post at Crown—part of a throng of fast-growing contract-research organizations in China.

Crown won’t divulge its full list of clients. But it includes heavyweights, including New York-based Pfizer Inc.

Lilly and many other pharmaceutical firms also are outsourcing an increasing amount of drug research here, as they struggle to lower drug-development costs and get new drugs to market faster. The entire industry is under unprecedented pressure as patents expire on the current crop of blockbusters.

“Many, many companies come to this part of the world because of the lower cost and the talent,” said Shih, co-inventor of Lilly’s Alimta, a lung cancer drug with $2.2 billion in annual sales.

He said the Chinese government adds to the allure of using CROs here by providing them lucrative incentives that further reduce expenses.

Faming Zhang, a former Lilly executive and Indiana University professor, founded Crown five years ago. Company officials have raked in tens of millions of dollars in venture capital and eventually hope to take the company public.

They certainly have plenty of growth to tout. Crown employs 180 in Beijing and another 170 outside Shanghai, and the company plans to add another 180 outside Shanghai by the end of this year. Researchers work in laboratories to create potential new drugs and test them on mice, monkeys and other animals.

Emerging competitor

The emergence of firms like Crown is a worrisome trend for the U.S. economy, said Benjamin Shobert, managing director of Teleos, an Indianapolis consulting firm.

“It could be the same sort of threat we face in manufacturing. But America believes it can afford to give away some of our high-labor-content, low-value-added manufacturing. We have to keep this kind of work,” Shobert said. “We have to show that, ‘Yeah, we’re more expensive, but we produce much more high-quality outputs,’ or we’ll lose that, too.”

For now, U.S.-trained scientists do maintain an edge over China-trained scientists, who generally have most of the basic skills they need but are less adept at creative problem solving, Shih said.

“You just have to develop a very good environment to nurture them and push them,” said Shih, one of several experienced researchers who worked in the United States and now are part of Crown’s management team.

Lilly’s CRO partners in China include WuXi AppTec and ChemExplorer. It also operates its own research-and-development center in Shanghai and is building a diabetes research center here.

The company hasn’t abandoned central Indiana, by any means. It still employs more than 10,300 people in the region, many in R&D.

But in an interview in Shanghai with IBJ last month, Lilly CEO John Lechleiter said CROs in China have more to offer than cost savings. “The skill level and the quality and the increasing availability of high-skilled and high-quality operations in the contract-research space renders these firms globally competitive,” he said.

Asked whether the emergence of high-quality pharmaceutical research in China puts research at risk in the United States, Lechleiter said: “There is not one easy answer. I will say I think our research tends to migrate to where the intellectual capital sits.”

In recent years, he said, Lilly has had difficulty getting green cards or permanent resident visas for some of the Chinese people graduating from American universities it wants to hire. “So we need to follow the talent, and I expect there will be people recruited to the U.S. who will want to stay in the U.S. And there will be Chinese people and others who want to come back here. Our research center in Shanghai gives them a place to land.”

Putting R&D in China also helps position companies to sell into the huge, emerging Chinese market, said Rachel Gong, an independent health care consultant in China.

But the cost savings are particularly compelling given the struggling pharmaceutical industry’s need to invent new drugs quickly and the high risk of failure. In the United States, a $100 million investment might advance just one or two drugs to late-stage development, she said. In China, that money might advance 10.•


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I took Bruce's comments to highlight a glaring issue when it comes to a state's image, and therefore its overall branding. An example is Michigan vs. Indiana. Michigan has done an excellent job of following through on its branding strategy around "Pure Michigan", even down to the detail of the rest stops. Since a state's branding is often targeted to visitors, it makes sense that rest stops, being that point of first impression, should be significant. It is clear that Indiana doesn't care as much about the impression it gives visitors even though our branding as the Crossroads of America does place importance on travel. Bruce's point is quite logical and accurate.

  2. I appreciated the article. I guess I have become so accustomed to making my "pit stops" at places where I can ALSO get gasoline and something hot to eat, that I hardly even notice public rest stops anymore. That said, I do concur with the rationale that our rest stops (if we are to have them at all) can and should be both fiscally-responsible AND designed to make a positive impression about our state.

  3. I don't know about the rest of you but I only stop at these places for one reason, and it's not to picnic. I move trucks for dealers and have been to rest areas in most all 48 lower states. Some of ours need upgrading no doubt. Many states rest areas are much worse than ours. In the rest area on I-70 just past Richmond truckers have to hike about a quarter of a mile. When I stop I;m generally in a bit of a hurry. Convenience,not beauty, is a primary concern.

  4. Community Hospital is the only system to not have layoffs? That is not true. Because I was one of the people who was laid off from East. And all of the LPN's have been laid off. Just because their layoffs were not announced or done all together does not mean people did not lose their jobs. They cherry-picked people from departments one by one. But you add them all up and it's several hundred. And East has had a dramatic drop I in patient beds from 800 to around 125. I know because I worked there for 30 years.

  5. I have obtained my 6 gallon badge for my donation of A Positive blood. I'm sorry to hear that my donation was nothing but a profit center for the Indiana Blood Center.